The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rituximab in the treatment of autoimmune haematological disorders
Open accessAbstract
Summary: Current treatment regimens for haematological autoimmune diseases are relatively non‐selective and are often associated with considerable toxicity. Recently, it has become clear that B cells play a key role in both the development and perpetuation of autoimmunity, suggesting that B‐cell depletion could be a valuable treatment approach for patients with autoimmune diseases. This article reviews data supporting the use of rituximab – an anti‐CD20 monoclonal antibody that specifically depletes B cells – in four key autoimmune haematological disorders: idiopathic thrombocytopenic purpura (ITP); autoimmune haemolytic anaemia (AIHA); acquired haemophilia; and thrombotic thrombocytopenic purpura (TTP). Although treatment of ITP, AIHA, acquired haemophilia and TTP with rituximab is still relatively uncommon, results from case series and small phase II trials indicate that patients of all ages can respond to rituximab, irrespective of the number or type of prior treatments that they have received. Moreover, patients with these diseases receiving rituximab experienced predominantly mild adverse events, with only a few serious adverse events reported. These data suggest that rituximab provides an effective and well‐tolerated alternative treatment option for patients with ITP, AIHA, acquired haemophilia and TTP, many of whom have limited treatment choices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Barcellini, W., Fattizzo, B., Zaninoni, A., Radice, T., Nichele, I., Di Bona, E., Lunghi, M., Tassinari, C., Alfinito, F., Ferrari, A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-583021 · Cited by 382
Patel, V. L., Mahévas, M., Lee, S. Y., Stasi, R., Cunningham-Rundles, S., Godeau, B., Kanter, J., Neufeld, E., Taube, T., Ramenghi, U., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393975 · Cited by 348
Michel, M., Chanet, V., Dechartres, A., Morin, A.-S., Piette, J.-C., Cirasino, L., Emilia, G., Zaja, F., Ruggeri, M., Andrès, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215368 · Cited by 316
Acquired factor VIII inhibitors
Franchini, M., & Lippi, G. (2008) · Blood · doi:10.1182/blood-2008-03-143586 · Cited by 267
Metadata
- Authors
- Garvey, B.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2008-03-18
- Volume
- 141
- Issue
- 2
- Pages
- 149-169
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2006456576
- Cited by
- 204
- References
- 1
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab in the treatment of autoimmune haematological disorders. https://app.cochat.ai/papers/10.1111/j.1365-2141.2008.07054.x
- The paper
- Garvey, B. (2008). Rituximab in the treatment of autoimmune haematological disorders. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2008.07054.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.